July 31, 2020
TEMPEST THERAPEUTICS TO PRESENT AT TWO INVESTOR CONFERENCES IN AUGUST
South San Francisco, CA – July 31, 2020 - Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class therapeutics that combine both precision and immune-mediated mechanisms, today announced that management will present at the following investor conferences in August 2020:
- 10th Annual William Blair BioTech Focus Conference on Tuesday, August 4th at 1:35 pm ET
- LifeSci Partners: Private Summer Symposium on Wednesday, August 5th at 1:30 pm ET
To access the live webcasts and subsequent archived recordings of these presentations, please visit the Tempest website at https://www.tempesttx.com/#investors.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both precision and immune-mediated mechanisms with the potential to target a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/4, respectively. Both TPST-1120 and TPST-1495 are progressing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an inhibitor of TREX-1, an exonuclease highly expressed in tumors that suppresses both STING and tumor immunity, to activate STING selectively in tumors via a systemically-delivered small molecule. Tempest is headquartered in South San Francisco and supported by notable healthcare investors. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Corporate Communications Contacts